Skip to main content

Compare Stocks

Date Range: 

 BeiGeneAstellas PharmaShiseidoTakeda PharmaceuticalRoyalty Pharma
SymbolNASDAQ:BGNEOTCMKTS:ALPMYOTCMKTS:SSDOYOTCMKTS:TKPYYNASDAQ:RPRX
Price Information
Current Price$323.67$15.34$70.56$17.20$41.50
52 Week RangeHoldBuyHoldN/AHold
MarketRank™
Overall Score1.31.70.91.01.7
Analysis Score2.20.00.00.02.2
Community Score2.82.72.22.72.7
Dividend Score0.02.51.70.81.7
Ownership Score0.80.00.00.00.8
Earnings & Valuation Score0.63.10.61.31.3
Analyst Ratings
Consensus RecommendationHoldBuyHoldN/AHold
Consensus Price Target$317.13N/AN/AN/A$51.88
% Upside from Price Target-2.02% downsideN/AN/AN/A25.00% upside
Trade Information
Market Cap$29.68 billion$28.56 billion$28.18 billion$26.87 billion$25.20 billion
Beta0.910.630.330.42N/A
Average Volume282,82275,53218,817979,6052,665,974
Sales & Book Value
Annual Revenue$428.21 million$11.97 billion$10.38 billion$15.99 billionN/A
Price / Sales69.312.392.711.68N/A
CashflowN/A$1.23 per share$3.38 per share$2.29 per shareN/A
Price / CashN/A12.4720.857.52N/A
Book Value$15.87 per share$6.28 per share$11.93 per share$11.62 per shareN/A
Price / Book20.402.445.911.48N/A
Profitability
Net Income$-948,630,000.00$1.80 billion$676.77 million$1.68 billionN/A
EPS($15.80)$0.96$1.72N/AN/A
Trailing P/E RatioN/A22.23N/A12.110.00
Forward P/E RatioN/A10.0975.8715.43
P/E GrowthN/AN/AN/AN/A1.94
Net Margins-569.22%11.03%-1.33%7.84%N/A
Return on Equity (ROE)-56.81%13.24%0.95%11.35%N/A
Return on Assets (ROA)-39.93%7.89%0.40%5.57%N/A
Dividend
Annual PayoutN/A$0.29$0.27$0.58$0.68
Dividend YieldN/A1.89%0.38%3.37%1.64%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/A30.21%15.70%N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/A1 Years
Debt
Debt-to-Equity Ratio0.04%N/A0.25%0.48%0.59%
Current Ratio7.69%1.23%1.11%1.42%10.31%
Quick Ratio7.64%0.99%0.68%1.12%10.31%
Ownership Information
Institutional Ownership Percentage60.65%0.18%0.14%0.19%40.85%
Insider Ownership Percentage9.00%N/AN/AN/A2.50%
Miscellaneous
Employees5,40015,88339,035N/AN/A
Shares Outstanding91.70 million1.86 billion399.39 million1.56 billion607.11 million
Next Earnings Date8/5/2021 (Estimated)8/3/2021 (Estimated)8/5/2021 (Estimated)N/A8/11/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Royalty Pharma (NASDAQ:RPRX) Announces Quarterly  Earnings ResultsRoyalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results
americanbankingnews.com - May 12 at 2:12 PM
Would I Choose Royalty Pharma plc (NASDAQ:RPRX) Stock at Any Point in Time?Would I Choose Royalty Pharma plc (NASDAQ:RPRX) Stock at Any Point in Time?
stocksregister.com - May 12 at 10:17 AM
Royalty Pharma: Q1 Earnings SnapshotRoyalty Pharma: Q1 Earnings Snapshot
chron.com - May 11 at 8:27 AM
Royalty Pharma Reports First Quarter 2021 ResultsRoyalty Pharma Reports First Quarter 2021 Results
finance.yahoo.com - May 11 at 8:27 AM
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
msn.com - May 10 at 12:25 PM
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
msn.com - May 9 at 3:19 PM
Royalty Pharma plc (RPRX): Price Now Near $41.94; Daily Chart Shows Downtrend on 100 Day BasisRoyalty Pharma plc (RPRX): Price Now Near $41.94; Daily Chart Shows Downtrend on 100 Day Basis
etfdailynews.com - May 8 at 1:47 AM
Royalty Pharma to Present at Upcoming Investor ConferencesRoyalty Pharma to Present at Upcoming Investor Conferences
benzinga.com - May 7 at 9:14 AM
Is Royalty Pharma plcs (NASDAQ:RPRX) 17% ROE Strong Compared To Its Industry?Is Royalty Pharma plc's (NASDAQ:RPRX) 17% ROE Strong Compared To Its Industry?
nasdaq.com - May 6 at 2:38 PM
Royalty Pharma: A Potentially Long-Term Dividend InvestmentRoyalty Pharma: A Potentially Long-Term Dividend Investment
seekingalpha.com - May 5 at 10:59 AM
Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
finance.yahoo.com - April 21 at 7:00 PM
MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences IndexesMSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
uk.finance.yahoo.com - April 21 at 1:59 PM
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences IndexesRoyalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
finance.yahoo.com - April 21 at 8:59 AM
Royalty Pharma Plc (RPRX)Royalty Pharma Plc (RPRX)
investing.com - April 18 at 10:37 PM
Royalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.9 million of SharesRoyalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.9 million of Shares
uk.finance.yahoo.com - April 16 at 11:05 PM
Royalty Pharma Declares Second-Quarter 2021 DividendRoyalty Pharma Declares Second-Quarter 2021 Dividend
finance.yahoo.com - April 15 at 9:42 AM
Insider Sells Royalty Pharmas SharesInsider Sells Royalty Pharma's Shares
benzinga.com - April 14 at 2:33 PM
Royalty Pharma Shows PromiseRoyalty Pharma Shows Promise
realmoney.thestreet.com - April 9 at 1:34 PM
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSKRoyalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
finance.yahoo.com - April 1 at 10:23 AM
Royalty Pharma Appoints Henry A. Fernandez as Lead Independent DirectorRoyalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
finance.yahoo.com - March 30 at 8:13 AM
Is Royalty Pharma a Biotech Stock Worth Buying?Is Royalty Pharma a Biotech Stock Worth Buying?
stocknews.com - March 26 at 12:39 PM
SYF vs. RPRX: Which Stock Should Value Investors Buy Now?SYF vs. RPRX: Which Stock Should Value Investors Buy Now?
msn.com - March 25 at 3:51 PM
Royalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.5 million of SharesRoyalty Pharma Plc (RPRX) EVP, Investments & GC George W. Lloyd Sold $2.5 million of Shares
finance.yahoo.com - March 24 at 7:51 PM
Royalty Pharma Plc (RPRX) EVP & CFO Terrance P. Coyne Sold $4.5 million of SharesRoyalty Pharma Plc (RPRX) EVP & CFO Terrance P. Coyne Sold $4.5 million of Shares
finance.yahoo.com - March 6 at 1:13 AM
Relative Strength Alert For Royalty PharmaRelative Strength Alert For Royalty Pharma
nasdaq.com - March 4 at 7:52 PM
DateCompanyBrokerageAction
5/17/2021BeiGeneMorgan StanleyLower Price Target
3/16/2021BeiGeneHSBCBoost Price Target
3/8/2021BeiGeneChina Renaissance SecuritiesInitiated Coverage
3/1/2021BeiGeneCLSADowngrade
2/25/2021BeiGeneCowenBoost Price Target
1/12/2021BeiGenePiper SandlerBoost Price Target
12/8/2020BeiGeneLADENBURG THALM/SH SHUpgrade
11/19/2020BeiGeneSVB LeerinkBoost Price Target
11/6/2020BeiGeneMaxim GroupDowngrade
5/26/2020Astellas PharmaThe Goldman Sachs GroupUpgrade
9/24/2019Astellas PharmaJefferies Financial GroupInitiated Coverage
11/5/2018Astellas PharmaJPMorgan Chase & Co.Downgrade
9/13/2018Astellas PharmaDeutsche Bank AktiengesellschaftDowngrade
11/11/2020ShiseidoDaiwa Capital MarketsUpgrade
11/9/2020Royalty PharmaUBS GroupUpgrade
7/14/2020Royalty PharmaEvercore ISIInitiated Coverage
7/13/2020Royalty PharmaBank of AmericaInitiated Coverage
7/13/2020Royalty PharmaCitigroupInitiated Coverage
7/13/2020Royalty PharmaSunTrust BanksInitiated Coverage
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.